Gilteritinib
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB12141 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 14 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | bulbar polio | KG + DL |
| 2 | acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent | KG + DL |
| 3 | acute myeloid leukemia and myelodysplastic syndromes related to radiation | KG + DL |
| 4 | 5q35 microduplication syndrome | KG + DL |
| 5 | neuralgic amyotrophy | KG + DL |
| 6 | amyotrophic neuralgia | KG + DL |
| 7 | vertebral anomalies and variable endocrine and T-cell dysfunction | KG + DL |
| 8 | ganglioneuroblastoma (disease) | KG + DL |
| 9 | retroperitoneal neoplasm | KG + DL |
| 10 | myelodysplastic/myeloproliferative disease | KG + DL |
| 11 | acute panmyelosis with myelofibrosis | KG + DL |
| 12 | neuroblastoma | KG + DL |
| 13 | bilineal acute myeloid leukemia | KG + DL |
| 14 | chronic myelogenous leukemia, BCR-ABL1 positive | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.